awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41014662-168363E4-D575-4B81-9421-884E06AD03E6
Q41014662-168363E4-D575-4B81-9421-884E06AD03E6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41014662-168363E4-D575-4B81-9421-884E06AD03E6
The transition from first-line to second-line therapy in multiple sclerosis.
P2860
Q41014662-168363E4-D575-4B81-9421-884E06AD03E6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41014662-168363E4-D575-4B81-9421-884E06AD03E6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dbeb28326b598163ebc2f8b1e94920a5a91b421a
P2860
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial